Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 34
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Biochim Biophys Acta Mol Cell Res ; 1867(1): 118569, 2020 01.
Artigo em Inglês | MEDLINE | ID: mdl-31676353

RESUMO

Water influx through aquaporin-1 (AQP-1) has been linked to the ability of different cell types to migrate, and therefore plays an important part in processes like metastasis and angiogenesis. Since the erythroid growth factor erythropoietin (Epo) is now recognized as an angiogenesis promoter, we investigated the participation of AQP-1 as a downstream effector of this cytokine in the migration of endothelial cells. Inhibition of AQP-1 with either mercury ions (Hg2+) or a specific siRNA led to an impaired migration of EA.hy926 endothelial cells exposed to Epo (wound-healing assays). Epo also induced the expression of AQP-1 at mRNA and protein levels, an effect which was dependent on the influx of extracellular calcium through L-type calcium channels as well as TRPC3 channels. The relationship between Epo and AQP-1 was further confirmed at shorter exposure times, as the cytokine was unable to trigger calcium influxes in cells where AQP-1 had previously been knocked down. Moreover, Epo promoted changes in the subcellular localization of AQP-1 as well as rearrangements in the actin cytoskeleton, which are consistent with a migratory phenotype. Worthy of note, carbamylated erythropoietin (cEpo), the non-erythropoietic and non-promigratory derivative of Epo, was incapable of AQP-1 modulation. The therapeutical implications of aquaporin targeting in angiogenesis-related diseases highlight the importance of the present results in the context of the relationship between AQP-1 and Epo.


Assuntos
Aquaporina 1/fisiologia , Movimento Celular/efeitos dos fármacos , Eritropoetina/farmacologia , Células Endoteliais da Veia Umbilical Humana/efeitos dos fármacos , Células Endoteliais da Veia Umbilical Humana/fisiologia , Células A549 , Aquaporina 1/antagonistas & inibidores , Movimento Celular/genética , Células Cultivadas , Eritropoetina/fisiologia , Humanos , RNA Interferente Pequeno/farmacologia , Cicatrização/efeitos dos fármacos , Cicatrização/genética
2.
Front Biosci (Elite Ed) ; 8(1): 100-12, 2016 01 01.
Artigo em Inglês | MEDLINE | ID: mdl-26709649

RESUMO

Erythropoiesis is a complex process that starts in the course of embryo formation and it is maintained throughout the life of an organism. During the fetal development, erythropoiesis arises from different body sites and erythroblast maturation occurs in the fetal liver. After birth, erythropoiesis and erythroblast maturation take place exclusively in the bone marrow, generating a lifetime reservoir of red blood cells (RBCs), which are responsible for transporting oxygen through the bloodstream to tissues and organs. Several transcription factors and cytokines, such as GATA-1, GATA-2, FOG-1 and erythropoietin (EPO), constitute an elaborated molecular network that regulates erythropoiesis as they are involved in the differentiation and maturation of RBCs. The profound understanding of erythropoiesis is fundamental to avoid, treat or even soften the effects of erythropoietic clinical disorders and may be useful to improve patients' well-being.


Assuntos
Eritropoese , Vertebrados/fisiologia , Fatores Etários , Animais , Eritropoetina/fisiologia , Feto/fisiologia , Hemoglobinas/fisiologia , Ferro/metabolismo
3.
Arq. bras. med. vet. zootec ; 65(1): 75-81, fev. 2013. graf, tab
Artigo em Português | LILACS | ID: lil-667539

RESUMO

Neste trabalho foi estudada a correlação entre o perfil proteico do plasma seminal e a motilidade e viabilidade espermática em coelhos submetidos ao tratamento com vetores de expressão contendo o gene da eritropoetina (EPO) e com EPO recombinante humana. Foram identificadas, em coelhos submetidos ao tratamento com vetor de DNA contendo o gene da EPO, duas bandas proteicas associadas a alterações na motilidade espermática - 48kDa à baixa motilidade (P<0,05) e 18kDa à alta motilidade (P<0,05) - e esse fator foi associado a maior viabilidade espermática (P<0,05). Em coelhos submetidos ao tratamento com EPO recombinante, um fator proteico, 63kDa, associou-se à alta motilidade espermática (P<0,05), enquanto dois, 26 e 40kDa, foram associados à alta viabilidade espermática (P<0,05). Esses resultados sugerem que o doping genético pode ocasionar mudanças no perfil proteico do plasma seminal, provocando alterações na motilidade e viabilidade espermática.


In this study the correlation between seminal plasma protein profile and the sperm motility and sperm viability in rabbits submitted to treatment with an expression vector containing EPO gene and with human recombinant EPO was evaluated. In rabbits submitted to treatment with EPO expression vector, two protein bands were associated to sperm motility - 48kDa associated to low motility (P<0.05) and 18kDa to high motility (P<0.05) - and this protein band was also associated to high sperm viability (P<0.05). In rabbits submitted to treatment with human recombinant EPO, a protein factor, 63kDa, was associated to high sperm motility (P<0.05) while two protein factors, 26 and 40kDa, were associated to high sperm viability (P<0.05). These results suggest that gene doping leads to changes in rabbit seminal plasma protein, altering sperm motility and sperm viability.


Assuntos
Animais , Coelhos , Análise do Sêmen/veterinária , Eritropoetina/análise , Eritropoetina/fisiologia , Miostatina/análise , Coelhos/genética , Reprodução , Sêmen/imunologia , Sêmen/parasitologia , Medicina Veterinária
4.
Artigo em Português | MEDLINE | ID: mdl-24646931

RESUMO

The hormonal abuse in physical exercise practioners is very common. Many pleople believe these substances can promote skeletal muscle hyperthrophy and improve physical fitness without health damaging effects. However, this is another myth that science unmasked. This article updates information regarding abuse of insulin, growth hormone, thyroid hormones, and erythropoitin. The peptide hormone abuse can cause motor paralysis, skeletal muscle damage and loss, diabetes mellitus, hypothyroidism, arterial hypertension, sweating, headaches, vomiting and enhances the risk for atherosclerosis, thrombosis, osteoporosis, and cancer.


El abuso de hormonas en practicantes de ejercicios físicos es muy difundido. Muchas personas creen que estas sustancias pueden producirla hipertrofia muscular y mejorar el estado físico sin traer daños a la salud. Sin embargo, esto es sólo un mito desacreditado por la ciencia. En este artículo se actualizan las informaciones sobre el abuso de la insulina, hormonas del crecimiento, hormonas tiroideas yeritropoyetina. El abuso de hormonas de la proteína (péptido) puede causar parálisis motora, lesión y pérdida de la masa muscular, la diabetes mellitus, hipotiroidismo, hipertensión arterial, sudoración, dolor de cabeza, vómitos y aumenta el riesgo de arterioesclerosis, trombosis, osteoporosis y cáncer. Palabras-clave: IGF-1, insulina, diabetes, hipertensión, hipotiroidismo.


Assuntos
Exercício Físico , Hormônios Peptídicos/efeitos adversos , Esportes , Eritropoetina/efeitos adversos , Eritropoetina/fisiologia , Exercício Físico/fisiologia , Hormônio do Crescimento/efeitos adversos , Hormônio do Crescimento/fisiologia , Humanos , Insulinas/efeitos adversos , Insulinas/fisiologia , Hormônios Peptídicos/fisiologia , Esportes/fisiologia , Hormônios Tireóideos/efeitos adversos , Hormônios Tireóideos/fisiologia
5.
Artigo em Espanhol | LILACS, BINACIS | ID: biblio-1170948

RESUMO

The hormonal abuse in physical exercise practioners is very common. Many pleople believe these substances can promote skeletal muscle hyperthrophy and improve physical fitness without health damaging effects. However, this is another myth that science unmasked. This article updates information regarding abuse of insulin, growth hormone, thyroid hormones, and erythropoitin. The peptide hormone abuse can cause motor paralysis, skeletal muscle damage and loss, diabetes mellitus, hypothyroidism, arterial hypertension, sweating, headaches, vomiting and enhances the risk for atherosclerosis, thrombosis, osteoporosis, and cancer.


Assuntos
Esportes , Exercício Físico , Hormônios Peptídicos/efeitos adversos , Eritropoetina/efeitos adversos , Eritropoetina/fisiologia , Esportes/fisiologia , Exercício Físico/fisiologia , Hormônio do Crescimento/efeitos adversos , Hormônio do Crescimento/fisiologia , Hormônios Peptídicos/fisiologia , Hormônios Tireóideos/efeitos adversos , Hormônios Tireóideos/fisiologia , Humanos , Insulinas/efeitos adversos , Insulinas/fisiologia
6.
Arq. bras. med. vet. zootec ; 65(1): 75-81, 2013. graf, tab
Artigo em Português | VETINDEX | ID: vti-9857

RESUMO

Neste trabalho foi estudada a correlação entre o perfil proteico do plasma seminal e a motilidade e viabilidade espermática em coelhos submetidos ao tratamento com vetores de expressão contendo o gene da eritropoetina (EPO) e com EPO recombinante humana. Foram identificadas, em coelhos submetidos ao tratamento com vetor de DNA contendo o gene da EPO, duas bandas proteicas associadas a alterações na motilidade espermática - 48kDa à baixa motilidade (P<0,05) e 18kDa à alta motilidade (P<0,05) - e esse fator foi associado a maior viabilidade espermática (P<0,05). Em coelhos submetidos ao tratamento com EPO recombinante, um fator proteico, 63kDa, associou-se à alta motilidade espermática (P<0,05), enquanto dois, 26 e 40kDa, foram associados à alta viabilidade espermática (P<0,05). Esses resultados sugerem que o doping genético pode ocasionar mudanças no perfil proteico do plasma seminal, provocando alterações na motilidade e viabilidade espermática.(AU)


In this study the correlation between seminal plasma protein profile and the sperm motility and sperm viability in rabbits submitted to treatment with an expression vector containing EPO gene and with human recombinant EPO was evaluated. In rabbits submitted to treatment with EPO expression vector, two protein bands were associated to sperm motility - 48kDa associated to low motility (P<0.05) and 18kDa to high motility (P<0.05) - and this protein band was also associated to high sperm viability (P<0.05). In rabbits submitted to treatment with human recombinant EPO, a protein factor, 63kDa, was associated to high sperm motility (P<0.05) while two protein factors, 26 and 40kDa, were associated to high sperm viability (P<0.05). These results suggest that gene doping leads to changes in rabbit seminal plasma protein, altering sperm motility and sperm viability.(AU)


Assuntos
Animais , Coelhos , Análise do Sêmen/veterinária , Eritropoetina/análise , Eritropoetina/fisiologia , Miostatina/análise , Sêmen/imunologia , Sêmen/parasitologia , Coelhos/genética , Reprodução , Medicina Veterinária
7.
Artigo em Espanhol | BINACIS | ID: bin-132713

RESUMO

The hormonal abuse in physical exercise practioners is very common. Many pleople believe these substances can promote skeletal muscle hyperthrophy and improve physical fitness without health damaging effects. However, this is another myth that science unmasked. This article updates information regarding abuse of insulin, growth hormone, thyroid hormones, and erythropoitin. The peptide hormone abuse can cause motor paralysis, skeletal muscle damage and loss, diabetes mellitus, hypothyroidism, arterial hypertension, sweating, headaches, vomiting and enhances the risk for atherosclerosis, thrombosis, osteoporosis, and cancer.


Assuntos
Exercício Físico , Hormônios Peptídicos/efeitos adversos , Esportes , Eritropoetina/efeitos adversos , Eritropoetina/fisiologia , Exercício Físico/fisiologia , Hormônio do Crescimento/efeitos adversos , Hormônio do Crescimento/fisiologia , Humanos , Insulinas/efeitos adversos , Insulinas/fisiologia , Hormônios Peptídicos/fisiologia , Esportes/fisiologia , Hormônios Tireóideos/efeitos adversos , Hormônios Tireóideos/fisiologia
8.
Biochim Biophys Acta ; 1743(1-2): 29-36, 2005 Mar 22.
Artigo em Inglês | MEDLINE | ID: mdl-15777837

RESUMO

Erythropoietin (Epo) promotes the development of erythroid progenitors by triggering intracellular signals through the binding to its specific receptor (EpoR). Previous results related to the action of aluminum (Al) on erythropoiesis let us suggest that the metal affects Epo interaction with its target cells. In order to investigate this effect on cell activation by the Epo-EpoR complex, two human cell lines with different dependence on Epo were subjected to Al exposure. In the Epo-independent K562 cells, Al inhibited Epo antiapoptotic action and triggered a simultaneous decrease in protein and mRNA EpoR levels. On the other hand, proliferation of the strongly Epo-dependent UT-7 cells was enhanced by long-term Al treatment, in agreement with the upregulation of EpoR expression during Epo starvation. Results provide some clues to the way by which Epo supports cell survival and growth, and demonstrate that not all the intracellular factors needed to guarantee the different signaling pathways of Epo-cell activation are available or activated in cells expressing EpoR. This study then suggests that at least one of the mechanisms by which Al interfere with erythropoiesis might involve EpoR modulation.


Assuntos
Alumínio/farmacologia , Eritropoetina/fisiologia , Receptores da Eritropoetina/fisiologia , Apoptose , Western Blotting , Proliferação de Células , Sobrevivência Celular , Relação Dose-Resposta a Droga , Eritropoetina/química , Humanos , Imunoprecipitação , Células K562 , Microscopia de Fluorescência , Fosforilação , RNA Mensageiro/metabolismo , Receptores da Eritropoetina/química , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Transdução de Sinais , Fatores de Tempo , Regulação para Cima
9.
Br J Haematol ; 121(1): 180-6, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12670351

RESUMO

Mice myocardia, in which plasma erythropoietin (EPO) concentrations were modified in response to different experimental conditions, were studied to evaluate contractility (dF/dt). CF1 mice were randomly separated into four main groups: group I, normocythaemic normoxic; group II-a, normocythaemic intermittently exposed to hypobaria for 72 h; group II-b, normocythaemic intermittently exposed to hypobaria for 3 weeks; group III, hypertransfused polycythaemic exposed to 72 h hypobaria; and group IV, hypertransfused polycythaemic maintained in normobaric air. Plasma EPO, contractile studies and binding assays were performed. The dF/dt was significantly higher in group II-a than in group I and group II-b; but in groups III and IV, the dF/dt was reduced. The toxic action of ouabain was reduced and delayed in its onset, accompanied by increased numbers of 3H-ouabain binding sites in group II-a. Contractility was positively correlated with plasma EPO (pEPO) in the different groups. Treating group I with recombinant human (rHu)-EPO enhanced contractility while treating group II-a with a monoclonal anti-EPO decreased the dF/dt. The inhibition of enzymatic pathway(s) known to participate in the cytokines signal transduction, decreased the basal dF/dt values on atria from group II-a and on group I atria treated with rHu-EPO. The results demonstrated: (1) a cardiac non-haematopoietic effect of EPO; (2) that mice in which the pEPO concentration increased showed improvement in contractility and in the therapeutic action of ouabain; and (3) it is possible that EPO may act as a cardioprotective agent by modulating the cardiac Na+-K+ pump.


Assuntos
Eritropoetina/fisiologia , Hipóxia/tratamento farmacológico , Contração Miocárdica/efeitos dos fármacos , Animais , Anticorpos Monoclonais/farmacologia , Relação Dose-Resposta a Droga , Inibidores Enzimáticos/uso terapêutico , Eritropoetina/análise , Eritropoetina/imunologia , Eritropoetina/uso terapêutico , Feminino , Hipóxia/sangue , Camundongos , Ouabaína/uso terapêutico , Proteínas Recombinantes , ATPase Trocadora de Sódio-Potássio/antagonistas & inibidores , ATPase Trocadora de Sódio-Potássio/metabolismo
10.
Adv Exp Med Biol ; 543: 161-75, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14713121

RESUMO

Polycythemia is one of the key factors involved in the chronic mountain sickness syndrome, a condition frequent in Andean natives but whose causes still remain unclear. In theory, polycythemia may be secondary to abnormalities in ventilation, occurring during day or night (e.g. due to sleep abnormalities) stimulating excessive erythropoietin (Epo) production, or else it may result from either autogenous production, or from co-factors like cobalt. To assess the importance of these points, we studied subjects with or without polycythemia, born and living in Cerro de Pasco (Peru, 4330m asl, CP) and evaluated the relationship between Epo and respiratory variables both in CP and sea level. We also assessed the relationship between sleep abnormalities and the circadian rhythm of Epo. Polycythemic subjects showed higher Epo in all conditions, lower SaO2 and hypoxic ventilatory response, higher physiological dead space and higher CO2, suggesting ventilatory inefficiency. Epo levels could be highly modified by the level of oxygenation, and were related to similar directional changes in SaO2. Cobalt levels were normal in all subjects and correlated poorly with hematologic variables. The diurnal variations in Epo were grossly abnormal in polycythemic subjects, with complete loss of the circadian rhythm. These abnormalities correlated with the levels of hypoxemia during the night, but not with sleep abnormalities, which were only minor even in polycythemic subjects. The increased Epo production is mainly related to a greater ventilatory inefficiency, and not to altered sensitivity to hypoxia, cobalt or sleep abnormalities. Improving oxygenation can represent a possible therapeutic option for this syndrome.


Assuntos
Doença da Altitude/fisiopatologia , Doença da Altitude/etiologia , Sistema Nervoso Autônomo/fisiopatologia , Doença Crônica , Ritmo Circadiano , Eritropoetina/fisiologia , Humanos , Hipóxia/fisiopatologia , Indígenas Sul-Americanos , Peru , Policitemia/complicações , Policitemia/fisiopatologia , Fenômenos Fisiológicos Respiratórios , Sono/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA